Greenwich LifeSciences, Inc. (GLSI) — Financial statements
Income statement, balance sheet, and cash flow for Greenwich LifeSciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.1% | 0.00 | |
| Gross Profit | -0.00↑0.0% | -0.00↑0.0% | -0.00↑0.0% | -0.00↓0.1% | -0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 13↑68.2% | 8↑18.9% | 6↑81.9% | 4↑236.6% | 1 | |
| General & Administrative Expenses | 3↑87.8% | 2↑4.1% | 2↑50.7% | 1↑28.8% | 0.81 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↑87.8% | 2↑4.1% | 2↑50.7% | 1↑28.8% | 0.81 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 16↑71.7% | 9↑16.0% | 8↑74.9% | 5↑146.7% | 2 | |
| Total Costs & Expenses | 16↑71.7% | 9↑16.0% | 8↑74.9% | 5↑146.7% | 2 | |
| Operating Results | ||||||
| Operating Income | -16↓71.7% | -9↓16.0% | -8↓74.9% | -5↓146.7% | -2 | |
| Depreciation & Amortization | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.1% | 0.00 | |
| EBITDA | -16↓69.3% | -9↓16.0% | -8↓74.9% | -5↓147.0% | -2 | |
| EBIT | -16↓69.3% | -9↓16.0% | -8↓74.9% | -5↓146.7% | -2 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.22↓48.9% | 0.44↑102.8% | 0.22↑685.7% | 0.03↑3189.3% | 0.00 | |
| Interest Income | 0.22↓48.9% | 0.44↑102.8% | 0.22↑685.7% | 0.03↑3189.3% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -0.22 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.22↓48.9% | 0.44↑102.8% | 0.22↑685.7% | 0.03↑3189.3% | 0.00 | |
| Income Before Tax | -16↓77.6% | -9↓13.6% | -8↓71.2% | -5↓145.3% | -2 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -16↓77.6% | -9↓13.6% | -8↓71.2% | -5↓145.3% | -2 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -16↓77.6% | -9↓13.6% | -8↓71.2% | -5↓145.4% | -2 | |
| Bottom-Line Net Income | -16↓77.6% | -9↓13.6% | -8↓71.2% | -5↓145.3% | -2 | |
| EPS (Basic) | -1.21↓75.4% | -0.69↓13.1% | -0.61↓74.3% | -0.35↓133.3% | -0.15 | |
| EPS (Diluted) | -1.21↓75.4% | -0.69↓13.1% | -0.61↓74.3% | -0.35↓133.3% | -0.15 | |
| Weighted Average Shares | 13↑1.3% | 13↓0.5% | 13↓0.2% | 13↑1.9% | 13 | |
| Weighted Average Diluted Shares | 13↑1.3% | 13↓0.5% | 13↓0.2% | 13↑1.9% | 13 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.